Nita Dhakal Poudyal
Psychiatric/Mental Health · Indianapolis, INNPI 1033891601
Payments from drug & device makers
Across 147 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$694
- Neurocrine Biosciences, Inc.$519
- AbbVie$457
- E.r. Squibb & Sons, L.L.C.$258
- Alkermes, Inc.$248
- Corium, LLC$191
- plus $479 from 12 others
What the payments were for
- Food & beverage$2,844100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,844 in reported general payments places this provider in the 80th percentile of 729 psychiatric/mental health providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 34 | $90,812 |
| FanaptIloperidone | 23 | $45,866 |
| RexultiBrexpiprazole | 25 | $37,721 |
| VraylarCariprazine Hcl | 26 | $36,803 |
| Lurasidone Hcl | 62 | $21,782 |
| CaplytaLumateperone Tosylate | 12 | $20,419 |
| TrintellixVortioxetine Hydrobromide | 30 | $18,236 |
| Paliperidone ErPaliperidone | 59 | $11,567 |
| Divalproex Sodium ErDivalproex Sodium | 52 | $6,182 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 65 | $5,894 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $5,803 |
| Ziprasidone Hcl | 47 | $2,966 |
| Quetiapine Fumarate | 122 | $2,724 |
| Hydroxyzine Hcl | 105 | $2,607 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 37 | $2,453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Vanda Pharmaceuticals Inc.Fanapt | $694 | $45,86623 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $48 | $37,72125 claims |
| AbbVieVraylar | $457 | $36,80326 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $14 | $24,03945 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $117 | $20,41912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Indianapolis
- Sonya RuedlingerIndianapolis$134K
- Devan GravesIndianapolis$12K
- Clyde YanIndianapolis$9K
- Beth DelamboIndianapolis$7K
- Olga Marie JiodioIndianapolis$6K
- Lindsay RussellIndianapolis$5K
- Nina VoigtIndianapolis$5K
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.